How AstraZeneca Performed in the First Quarter
In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.